Gavin Cull

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S. Tam, Judith Trotman, Stephen Opat et al. · Blood · 2019 · 367 citations · Full text

Medicine, Oncology, Pharmacology +10

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina et al. · The Lancet Oncology · 2019 · 235 citations

Medicine, Oncology, Pharmacotherapy +10

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb et al. · Blood · 2020 · 111 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Meletios Α. Dimopoulos, Stephen Opat, Shirley D’Sa et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Hematology, Pharmacology +11